We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the third quarter, AstraZeneca reported revenues of $16.21 billion, up 7% year over year at constant exchange rates (CER). Revenues exceeded the Zacks Consensus Estimate of $16.1 billion. Core earnings of $2.79 per share also surpassed the Zacks Consensus Estimate of $2.60.
Strong Oncology growth, supported by Tagrisso, Imfinzi and Calquence, alongside increasing contributions from Tezspire, Fasenra and Ultomiris, helped offset weakness in mature brands. Newer drugs like Wainua, Saphnelo, Datroway and Truqap also contributed to top-line growth. However, continued generic pressure on Farxiga, Brilinta, Symbicort and Soliris hurt sales growth.
AstraZeneca reaffirmed its full-year 2026 guidance for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at CER.
On the call, AstraZeneca announced a three-year restructuring initiative, “Reshaping for Sustainable Growth,” aimed at optimizing resources and strengthening capabilities. The program is expected to incur up to $2 billion in one-time costs and generate $1.5 billion in annualized pretax savings, which will be reinvested in its pipeline, with completion targeted by the end of 2029.
However, a single quarter’s results are not so important for long-term investors, and the focus should rather be on the company’s strong fundamentals. Let’s understand AZN’s strengths and weaknesses to better analyze how to play the stock amid the latest price decline.
AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines.
AstraZeneca now has 16 blockbuster medicines, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [(MRK - Free Report) ]), Soliris and Ultomiris in its portfolio, with sales (product sales and alliance revenues) exceeding $1 billion. These drugs drove AstraZeneca’s 7% top-line growth and 14% core EPS at CER in the first nine months of 2026, backed by increasing demand trends. Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap also contributed to top-line growth. Almost every new product that has been launched in recent years has done well.
Oncology Remains AstraZeneca’s Key Growth Engine
Oncology is AstraZeneca’s biggest segment. The segment contributes roughly 46% of total product sales and continues to be the company’s primary growth driver.
AstraZeneca’s oncology sales were $21.9 billion in the first nine months of 2026, up 16% at CER. The strong oncology performance was driven by robust demand for drugs like Tagrisso, MRK-partnered Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Key new cancer drugs in AstraZeneca’s portfolio, Truqapand Datroway, co-developed with partner Daiichi, are also contributing to sales growth. Etcamah/camizestrant, an oral SERD, was approved for first-line advanced ER-positive, HER2-negative advanced breast cancer in the EU in July 2026 and in the United States in September 2026.
AstraZeneca is working to strengthen its oncology product portfolio through label expansions of existing products like Tagrisso, Imfinzi, Truqap and Datroway. AstraZeneca also possesses one of the deepest late-stage oncology pipelines in the industry. Its key late-stage oncology pipeline candidates include sonesitatug vedotin, surovatamig and rilvegostomig, targeting gastric/GEJ adenocarcinoma, B-cell lymphomas and NSCLC and gastrointestinal cancers.
AstraZeneca expects oncology to continue to drive growth through 2030 and well beyond.
AZN Eyes $80B Revenues by 2030 With a Strong Launch Pipeline
AstraZeneca has set itself some visible targets for the next few years. It expects to generate $80 billion in total revenues by 2030. By that time frame, AstraZeneca plans to launch 20 new medicines, with around 14 already launched/approved. In 2026, AstraZeneca has gained approval for four new medicines, Etcamah and Baxfendy in the United States and Klygefa and Amlypave in Japan.
AstraZeneca believes that many of these new medicines, like Datroway, Etcamah and Baxfendy, have peak-year revenue potential of more than $5 billion.
Beyond these launches, AstraZeneca boasts a deep late-stage pipeline of multiple blockbuster opportunities. It has more than 20 key phase III readouts (both oncology and non-oncology) planned for 2027, with potential non-risk-adjusted peak-year revenues of more than $20 billion. This includes pivotal data readouts for nine potential new medicines.
AZN’s Several Recent Pipeline Setbacks
AstraZeneca faced several recent pipeline setbacks. In July, Wainua’s CARDIO-TTRansform study failed to meet its primary endpoint in ATTR-CM, limiting its expansion beyond the smaller ATTRv-PN market. Ultomiris also failed to achieve statistical significance in a phase III study in HSCT-TMA. In August, AstraZeneca discontinued the phase III eVOLVE-Lung02 study of experimental bispecific antibody volrustomig in NSCLC due to futility. In September, Etcamah failed to achieve a statistically significant improvement in progression-free survival in the phase III SERENA-4 study involving previously untreated patients with ER-positive, HER2-negative advanced breast cancer.
Headwinds Hurting AZN’s Top Line
Recently, several of the company’s established medicines like Brilinta, Farxiga, Symbicort and Soliris have lost exclusivity and are facing generic erosion. Generic versions of Brilinta were launched in the United States and Europe in 2025, which are hurting sales of the drug. Biosimilar versions of Soliris were launched in the United States and EU in 2025. Generic versions of Farxiga have been launched in the United Kingdom, United States, Japan and China, and revenues are declining sharply.
China, though an important market for AstraZeneca, remains a somewhat uncertain market due to pricing pressure from volume-based procurement (VBP) programs and ongoing legal and compliance investigations involving the company’s former China head, Leon Wang. China contributes roughly 12% of the company's revenues.
AZN Stock’s Price, Valuation & Estimates
AstraZeneca’s stock is at break-even so far this year compared with an increase of 26.5% for the industry.
AZN Stock Underperforms Industry
Image Source: Zacks Investment Research
From a valuation standpoint, AstraZeneca is decently valued. Going by the price/earnings ratio, the company’s shares currently trade at 16.42 forward earnings, lower than 19.88 for the industry. AZN’s stock is also trading below its 5-year mean of 17.58. The stock is, however, cheaper than other large drugmakers like Eli Lilly (LLY - Free Report) , AbbVie, Merck, Gilead and J&J (JNJ - Free Report) .
AZN Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has declined from $10.23 per share to $10.22 per share over the past 30 days. For 2027, earnings estimates have declined from $11.37 per share to $11.34 per share over the same timeframe.
AZN Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in AZN Stock
AstraZeneca’s stock has declined this year, accompanied by slight downward revisions to earnings estimates. In addition, several of the company’s established medicines are facing patent expirations and pricing pressures, creating uncertainty about whether revenues from these mature products can be replaced quickly enough by newer launches and pipeline candidates. The company has also experienced several recent clinical setbacks,
However, despite the headwinds, AZN expects continued revenue and earnings growth in 2026. It expects total revenues to grow by a mid-to-high single-digit percentage at CER in 2026, while core EPS is expected to increase by a low double-digit percentage at CER.
With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, it remains confident of achieving its 2030 goals to sustain growth through the next decade.
Image: Bigstock
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
Key Takeaways
AstraZeneca (AZN - Free Report) stock has risen 12.2% in a month, primarily driven by better-than-expected third-quarter 2026 results, strong oncology sales and improving investor confidence in the company’s long-term growth prospects.
In the third quarter, AstraZeneca reported revenues of $16.21 billion, up 7% year over year at constant exchange rates (CER). Revenues exceeded the Zacks Consensus Estimate of $16.1 billion. Core earnings of $2.79 per share also surpassed the Zacks Consensus Estimate of $2.60.
Strong Oncology growth, supported by Tagrisso, Imfinzi and Calquence, alongside increasing contributions from Tezspire, Fasenra and Ultomiris, helped offset weakness in mature brands. Newer drugs like Wainua, Saphnelo, Datroway and Truqap also contributed to top-line growth. However, continued generic pressure on Farxiga, Brilinta, Symbicort and Soliris hurt sales growth.
AstraZeneca reaffirmed its full-year 2026 guidance for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at CER.
On the call, AstraZeneca announced a three-year restructuring initiative, “Reshaping for Sustainable Growth,” aimed at optimizing resources and strengthening capabilities. The program is expected to incur up to $2 billion in one-time costs and generate $1.5 billion in annualized pretax savings, which will be reinvested in its pipeline, with completion targeted by the end of 2029.
However, a single quarter’s results are not so important for long-term investors, and the focus should rather be on the company’s strong fundamentals. Let’s understand AZN’s strengths and weaknesses to better analyze how to play the stock amid the latest price decline.
Strong Blockbuster Portfolio Drives AZN’s Revenue Growth
AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines.
AstraZeneca now has 16 blockbuster medicines, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [(MRK - Free Report) ]), Soliris and Ultomiris in its portfolio, with sales (product sales and alliance revenues) exceeding $1 billion. These drugs drove AstraZeneca’s 7% top-line growth and 14% core EPS at CER in the first nine months of 2026, backed by increasing demand trends. Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap also contributed to top-line growth. Almost every new product that has been launched in recent years has done well.
Oncology Remains AstraZeneca’s Key Growth Engine
Oncology is AstraZeneca’s biggest segment. The segment contributes roughly 46% of total product sales and continues to be the company’s primary growth driver.
AstraZeneca’s oncology sales were $21.9 billion in the first nine months of 2026, up 16% at CER. The strong oncology performance was driven by robust demand for drugs like Tagrisso, MRK-partnered Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Key new cancer drugs in AstraZeneca’s portfolio, Truqapand Datroway, co-developed with partner Daiichi, are also contributing to sales growth. Etcamah/camizestrant, an oral SERD, was approved for first-line advanced ER-positive, HER2-negative advanced breast cancer in the EU in July 2026 and in the United States in September 2026.
AstraZeneca is working to strengthen its oncology product portfolio through label expansions of existing products like Tagrisso, Imfinzi, Truqap and Datroway. AstraZeneca also possesses one of the deepest late-stage oncology pipelines in the industry. Its key late-stage oncology pipeline candidates include sonesitatug vedotin, surovatamig and rilvegostomig, targeting gastric/GEJ adenocarcinoma, B-cell lymphomas and NSCLC and gastrointestinal cancers.
AstraZeneca expects oncology to continue to drive growth through 2030 and well beyond.
AZN Eyes $80B Revenues by 2030 With a Strong Launch Pipeline
AstraZeneca has set itself some visible targets for the next few years. It expects to generate $80 billion in total revenues by 2030. By that time frame, AstraZeneca plans to launch 20 new medicines, with around 14 already launched/approved. In 2026, AstraZeneca has gained approval for four new medicines, Etcamah and Baxfendy in the United States and Klygefa and Amlypave in Japan.
AstraZeneca believes that many of these new medicines, like Datroway, Etcamah and Baxfendy, have peak-year revenue potential of more than $5 billion.
Beyond these launches, AstraZeneca boasts a deep late-stage pipeline of multiple blockbuster opportunities. It has more than 20 key phase III readouts (both oncology and non-oncology) planned for 2027, with potential non-risk-adjusted peak-year revenues of more than $20 billion. This includes pivotal data readouts for nine potential new medicines.
AZN’s Several Recent Pipeline Setbacks
AstraZeneca faced several recent pipeline setbacks. In July, Wainua’s CARDIO-TTRansform study failed to meet its primary endpoint in ATTR-CM, limiting its expansion beyond the smaller ATTRv-PN market. Ultomiris also failed to achieve statistical significance in a phase III study in HSCT-TMA. In August, AstraZeneca discontinued the phase III eVOLVE-Lung02 study of experimental bispecific antibody volrustomig in NSCLC due to futility. In September, Etcamah failed to achieve a statistically significant improvement in progression-free survival in the phase III SERENA-4 study involving previously untreated patients with ER-positive, HER2-negative advanced breast cancer.
Headwinds Hurting AZN’s Top Line
Recently, several of the company’s established medicines like Brilinta, Farxiga, Symbicort and Soliris have lost exclusivity and are facing generic erosion. Generic versions of Brilinta were launched in the United States and Europe in 2025, which are hurting sales of the drug. Biosimilar versions of Soliris were launched in the United States and EU in 2025. Generic versions of Farxiga have been launched in the United Kingdom, United States, Japan and China, and revenues are declining sharply.
China, though an important market for AstraZeneca, remains a somewhat uncertain market due to pricing pressure from volume-based procurement (VBP) programs and ongoing legal and compliance investigations involving the company’s former China head, Leon Wang. China contributes roughly 12% of the company's revenues.
AZN Stock’s Price, Valuation & Estimates
AstraZeneca’s stock is at break-even so far this year compared with an increase of 26.5% for the industry.
AZN Stock Underperforms Industry
From a valuation standpoint, AstraZeneca is decently valued. Going by the price/earnings ratio, the company’s shares currently trade at 16.42 forward earnings, lower than 19.88 for the industry. AZN’s stock is also trading below its 5-year mean of 17.58. The stock is, however, cheaper than other large drugmakers like Eli Lilly (LLY - Free Report) , AbbVie, Merck, Gilead and J&J (JNJ - Free Report) .
AZN Stock Valuation
The Zacks Consensus Estimate for 2026 earnings has declined from $10.23 per share to $10.22 per share over the past 30 days. For 2027, earnings estimates have declined from $11.37 per share to $11.34 per share over the same timeframe.
AZN Estimate Movement
Stay Invested in AZN Stock
AstraZeneca’s stock has declined this year, accompanied by slight downward revisions to earnings estimates. In addition, several of the company’s established medicines are facing patent expirations and pricing pressures, creating uncertainty about whether revenues from these mature products can be replaced quickly enough by newer launches and pipeline candidates. The company has also experienced several recent clinical setbacks,
However, despite the headwinds, AZN expects continued revenue and earnings growth in 2026. It expects total revenues to grow by a mid-to-high single-digit percentage at CER in 2026, while core EPS is expected to increase by a low double-digit percentage at CER.
With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, it remains confident of achieving its 2030 goals to sustain growth through the next decade.
Considering AZN’s growth prospects, one should stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.